Salvage Autologous Hematopoietic Stem Cell Transplantation Versus Chemoimmunotherapy in Relapsed Multiple Myeloma Patients After First Transplantation; Single Center Data

Ferda Can

Makale detayları

Salvage Autologous Hematopoietic Stem Cell Transplantation Versus Chemoimmunotherapy in Relapsed Multiple Myeloma Patients After First Transplantation; Single Center Data

Yazarlar:

Ferda Can

Yayıncı:

Ankara University

Ana Başlıklar:

Haematology

Dergi:

Ankara Üniversitesi Tıp Fakültesi Mecmuası Vol.76 Issue 3, pp.200-205

Belge Tipi:

Makale

Yayın Tarihi:

10/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001349849

pISSN:

0365-8104

Anahtar kelimeler:

Özet:

 Objectives: Multiple myeloma MM is an uncurable disease and standard therapy for relapsed MM is still not clear. We aimed to compare salvagetreatments for relapsed refractory MM. Materials and Methods: Sixty patients who relapsed after first autologous stem cell transplantation ASCT were analyzed. Twenty-seven patients were treated with salvage chemoimmunotherapy CIT. Thirty-three were treated with salvage ASCT. Results: There was no difference between treatment arms in terms of gender, age and disease characteristics. Median progression-free survival PFS was significantly better in ASCT group than CIT group 25 months vs. 12 months; p0.01. PFS rates on the first and second year were also better in ASCT group. Median overall survival in ASCT group was longer than CIT 73 vs. 30 months, although it did not reach a statistical significance p0.09. Time to achieving the best response after ASCT and CIT was 1 0-9 month versus 6.5 2-15 months p0.02. All grade toxicities were similar in both groups ASCT 57.6 vs. CIT 48.1 p0.6. Grade 3 or 4 toxicities were similar ASCT 19, CIT 13 in both groups p0.4. In the approximate cost analysis made with current pricing in December 2022 in our country, ASCT was more economical than CIT 380 600  vs. 393 860 . Conclusion: Salvage ASCT may provide longer PFS with similar toxicity profile and more cost-effective therapy profile than salvage CIT. It is suggested that earlier and better responses, long-term PFS can be achieved with salvage ASCT.

 Objectives: Multiple myeloma MM is an uncurable disease and standard therapy for relapsed MM is still not clear. We aimed to compare salvagetreatments for relapsed refractory MM. Materials and Methods: Sixty patients who relapsed after first autologous stem cell transplantation ASCT were analyzed. Twenty-seven patients were treated with salvage chemoimmunotherapy CIT. Thirty-three were treated with salvage ASCT. Results: There was no difference between treatment arms in terms of gender, age and disease characteristics. Median progression-free survival PFS was significantly better in ASCT group than CIT group 25 months vs. 12 months; p0.01. PFS rates on the first and second year were also better in ASCT group. Median overall survival in ASCT group was longer than CIT 73 vs. 30 months, although it did not reach a statistical significance p0.09. Time to achieving the best response after ASCT and CIT was 1 0-9 month versus 6.5 2-15 months p0.02. All grade toxicities were similar in both groups ASCT 57.6 vs. CIT 48.1 p0.6. Grade 3 or 4 toxicities were similar ASCT 19, CIT 13 in both groups p0.4. In the approximate cost analysis made with current pricing in December 2022 in our country, ASCT was more economical than CIT 380 600  vs. 393 860 . Conclusion: Salvage ASCT may provide longer PFS with similar toxicity profile and more cost-effective therapy profile than salvage CIT. It is suggested that earlier and better responses, long-term PFS can be achieved with salvage ASCT.

 Objectives: Multiple myeloma MM is an uncurable disease and standard therapy for relapsed MM is still not clear. We aimed to compare salvagetreatments for relapsed refractory MM. Materials and Methods: Sixty patients who relapsed after first autologous stem cell transplantation ASCT were analyzed. Twenty-seven patients were treated with salvage chemoimmunotherapy CIT. Thirty-three were treated with salvage ASCT. Results: There was no difference between treatment arms in terms of gender, age and disease characteristics. Median progression-free survival PFS was significantly better in ASCT group than CIT group 25 months vs. 12 months; p0.01. PFS rates on the first and second year were also better in ASCT group. Median overall survival in ASCT group was longer than CIT 73 vs. 30 months, although it did not reach a statistical significance p0.09. Time to achieving the best response after ASCT and CIT was 1 0-9 month versus 6.5 2-15 months p0.02. All grade toxicities were similar in both groups ASCT 57.6 vs. CIT 48.1 p0.6. Grade 3 or 4 toxicities were similar ASCT 19, CIT 13 in both groups p0.4. In the approximate cost analysis made with current pricing in December 2022 in our country, ASCT was more economical than CIT 380 600  vs. 393 860 . Conclusion: Salvage ASCT may provide longer PFS with similar toxicity profile and more cost-effective therapy profile than salvage CIT. It is suggested that earlier and better responses, long-term PFS can be achieved with salvage ASCT.

 Objectives: Multiple myeloma MM is an uncurable disease and standard therapy for relapsed MM is still not clear. We aimed to compare salvagetreatments for relapsed refractory MM. Materials and Methods: Sixty patients who relapsed after first autologous stem cell transplantation ASCT were analyzed. Twenty-seven patients were treated with salvage chemoimmunotherapy CIT. Thirty-three were treated with salvage ASCT. Results: There was no difference between treatment arms in terms of gender, age and disease characteristics. Median progression-free survival PFS was significantly better in ASCT group than CIT group 25 months vs. 12 months; p0.01. PFS rates on the first and second year were also better in ASCT group. Median overall survival in ASCT group was longer than CIT 73 vs. 30 months, although it did not reach a statistical significance p0.09. Time to achieving the best response after ASCT and CIT was 1 0-9 month versus 6.5 2-15 months p0.02. All grade toxicities were similar in both groups ASCT 57.6 vs. CIT 48.1 p0.6. Grade 3 or 4 toxicities were similar ASCT 19, CIT 13 in both groups p0.4. In the approximate cost analysis made with current pricing in December 2022 in our country, ASCT was more economical than CIT 380 600  vs. 393 860 . Conclusion: Salvage ASCT may provide longer PFS with similar toxicity profile and more cost-effective therapy profile than salvage CIT. It is suggested that earlier and better responses, long-term PFS can be achieved with salvage ASCT.

Makale detayları

Salvage Autologous Hematopoietic Stem Cell Transplantation Versus Chemoimmunotherapy in Relapsed Multiple Myeloma Patients After First Transplantation; Single Center Data

Yazarlar:

Ferda Can

Yayıncı:

Ankara University

Ana Başlıklar:

Haematology

Dergi:

Ankara Üniversitesi Tıp Fakültesi Mecmuası Vol.76 Issue 3, pp.200-205

Belge Tipi:

Makale

Yayın Tarihi:

10/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001349849

pISSN:

0365-8104

Multiple Myeloma

Relapsed

Salvage Transplantation

Chemoimmunotherapy

Second Autologous

Stem Cell Transplantation

Sayı

Makale detayları

Salvage Autologous Hematopoietic Stem Cell Transplantation Versus Chemoimmunotherapy in Relapsed Multiple Myeloma Patients After First Transplantation; Single Center Data

Yazarlar: Ferda Can

Yayıncı: Ankara University

Ana Başlıklar: Haematology

Dergi: Ankara Üniversitesi Tıp Fakültesi Mecmuası Vol.76 Issue 3, pp.200-205

Belge Tipi: Makale

Yayın Tarihi: 10/2023

Belge Dili: İngilizce

Document ID (Org No.): 2001349849

pISSN: 0365-8104

Multiple Myeloma

Relapsed

Salvage Transplantation

Chemoimmunotherapy

Second Autologous

Stem Cell Transplantation

Sayı

Yazarlar:

Ferda Can

Yayıncı:

Ankara University

Ana Başlıklar:

Haematology

Dergi:

Ankara Üniversitesi Tıp Fakültesi Mecmuası Vol.76 Issue 3, pp.200-205

Belge Tipi:

Makale

Yayın Tarihi:

10/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001349849

pISSN:

0365-8104